Introduction
============

Antibodies are Y-shaped globular proteins, namely Ig, that are produced by the immune system in most vertebrates ([@B2]). The Ig molecules typically consist of two identical heavy chains (IGH) and two light chains (IGL or IGK) ([@B24]). They are either secreted by or presented on the surface of B lymphocytes fulfilling crucial functions during the course of humoral immune responses to prevent or combat infections ([@B17]). The antigen-binding specificity is mainly determined by the antibody variable region, which is assembled from germline variable (V), diversity (D) for heavy chain, and joining (J) gene segments ([@B36]). The number of functional V, D, and J genes is limited across different species. However, the immune system has evolved a complex process to generate antibody repertoire with almost infinite diversity, mainly through random nucleotide insertions and deletions at V(D)J junctions, and somatic hypermutation (SHM) ([@B36]).

As each antibody has precise specificity for a given antigen, mAbs are widely used in biological research, clinical diagnosis, and therapy ([@B3]). Various techniques have been developed to isolate mAbs from humans and immunized animals. Hybridomas and Epstein-Barr Virus (EBV) immortalized B cells are among the most commonly used platforms, however, the efficiency of each technology is relatively low, which compromises sampling the diversity of immune repertoire ([@B20]; [@B10]). While antibody display methodologies such as phage and yeast display libraries are widely adopted for mAb isolation, they are prone to generate biased repertoires and lose information of natural pairing ([@B22]). Single B cell technologies have evolved rapidly in recent years ([@B33]; [@B28]), and have been applied to isolate numerous bNAbs against HIV, Ebola, and influenza ([@B6]; [@B15]; [@B37]). Strategies to directly clone antibody sequences from single B cells for mouse, rabbit and macaque models have subsequently been developed to characterize immune responses at high resolutions ([@B27]; [@B26]; [@B16]; [@B25]).

The guinea pig is considered as the premier model in the study of infectious diseases ([@B19]). It shares many similarities to humans regarding symptoms and immune responses to infections and therapies ([@B29]; [@B19]). Additionally, unlike other small animal models such as the mouse model, the guinea pig model allows sampling significant blood volumes for downstream immunological analysis. Despite these advantages, the immune response of guinea pig model is still relatively understudied, which is largely due to the shortage of guinea pig-specific immune reagents and the lack of basic knowledge about Ig genes ([@B29]). To delineate the epitope specificity of B cell responses in guinea pigs, we established an antigen-specific single B cell sorting and mAb-cloning platform for the guinea pig model. By using newly designed guinea pig Ig gene-specific primers, we directly cloned and expressed antigen-specific mAbs from B cells isolated from guinea pigs immunized with HIV-1 envelope glycoprotein (Env) vaccine candidate BG505 SOSIP by FACS-based single cell sorting. This platform allows us to delineate antigen-specific antibody responses in guinea pigs at the clonal level for better understanding the immunogenicity of vaccine candidates and the effect of immunization strategies. Furthermore, this methodology is applicable for isolating/developing essential research reagents and therapeutic mAbs from guinea pigs in the future.

Materials and Methods {#s1}
=====================

Animal Immunization and Sampling
--------------------------------

The guinea pig used in this study, designated as 1567, was immunized in a previous study ([@B5]). Briefly, along with another five guinea pigs in the same group, animal 1567 was immunized four times at weeks 0, 4, 12, and 24 with HIV-1 Env trimer BG505 SOSIP formulated in ISOMATRIX adjuvant. Blood samples were harvested 2 weeks after each immunization with the terminal bleed on week 46 to prepare for PBMC and sera for downstream analysis ([@B5]; [Figure 1A,B](#F1){ref-type="fig"}). Four days prior to the termination, an inoculation of 40 μg of Env trimer BG505 SOSIP in the absence of adjuvant was administered by intraperitoneal injection (IP) route. The PBMCs from whole blood were further purified by density gradient centrifugation with Ficoll-Paque PLUS (GE Healthcare). After washing by PBS, cells were resuspended and frozen gradually in Bambanker media (Wako Chemicals) at -80°C followed by storage in liquid nitrogen prior to the staining and sorting experiment. The animal study was carried out at Covance with the protocol approved by the Covance Institutional Animal Care and Use Committee (IACUC, protocol \#0138-14).

![Isolation of vaccine-induced antigen-specific guinea pig B cells. **(A)** Guinea pigs (*n* = 6) were immunized at week 0, 4, 12, and 24 with BG505 SOSIP formulated in ISCOMATRIX adjuvant via intramuscular (IM) route. Serum sampling was performed at weeks indicated in the scheme. On week 45, BG505 SOSIP was injected by intraperitoneal (IP) route followed by termination bleed on week 46 and collection of spleens for splenocytes. **(B)** Neutralization ID~50~ titers (reciprocal serum dilution factor) of plasma collected at week 26 from guinea pigs against a panel of tier 1 and tier 2 viruses using the TZM-bl pseudovirus assay. The data are representative of at least two independent experiments. **(C)** Single B cell isolation was performed in an antigen-selective manner by multicolor fluorescenceactivated cell sorting (FACS). Peripheral blood mononuclear cells (PBMCs) from guinea pig 1567 on week 46 were stained by a cocktail of fluorochrome-conjugated antibodies and antigens for identifying IgG^hi^ IgM^lo^ B cell subpopulations with dual positive binding to BG505 SOSIP trimers to minimize non-specific antigen probe binding.](fmicb-10-00672-g001){#F1}

Isolation of Single Guinea Pig B Cells by Fluorescence-Activated Cell Sorting (FACS)
------------------------------------------------------------------------------------

Guinea pig PBMCs were thawed and re-suspended in 10 ml of pre-warmed RPMI 1640 medium (Gibco) supplemented with 10% FBS (Gibco) (R10) and 10 μl of DNase I (Roche). The cells were washed and re-suspended with 45 μl of pre-chilled phosphate-buffered saline (PBS). Five microliters of 40-fold water-diluted Live/dead fixable aqua dead stain (Invitrogen) was added to the cells followed by incubation in the dark at 4°C for 10 min. The cells were further stained by adding 50 μl of antibody cocktail in R10 medium containing anti-guinea pig IgM-FITC (100-fold dilution, Antibodies-online, ABIN457754), anti-guinea pig IgG-Alexa Fluor 594 (100-fold dilution, Jackson ImmunoResearch, 116790), and biotin-labeled HIV-1 Env trimer BG505 SOSIP conjugated with streptavidin-PE (Invitrogen) and streptavidin-APC (Invitrogen), respectively, at 4 μg/ml as described previously ([@B34]). The cell and antibody cocktail mixture was incubated in the dark at 4°C for 1 h. After staining, the cells were washed and re-suspended in 0.5 ml of pre-chilled R10 medium and passed through a 70 μm cell strainer (BD Biosciences) prior to cell sorting. Three microliters of Dynabeads^TM^ Protein G (Invitrogen) stained with the same volume of anti-guinea pig IgM-FITC and anti-guinea pig IgG-Alexa Fluor 594, respectively, as well as 20 μl of biotin bead (Spherotech, TP-30-5) stained with 0.1 μl of streptavidin-PE and streptavidin-APC, respectively, in a total volume of 100 μl at room temperature for 20 min, were used for compensation.

Antigen-specific single B cells were identified and sorted by a FACS Aria III cell sorter (BD Biosciences) at single cell density into 96-well PCR plates containing 20 μl of lysis buffer as previously described ([@B26]). A representative example of FACS gating strategy used for identifying HIV Ag BG505 SOSIP-dual positive single B cells is shown in [Figure 1C](#F1){ref-type="fig"}. In brief, after the gating of lymphocytes (SSC-A vs. FSC-A) and singlets (FSC-H vs. FSC-A), live cells were identified by the negative aqua blue staining phenotype. Antigen-specific IgG^hi^ B cells were then determined as IgG^hi^ IgM^lo^ and dual positive (PE^+^ APC^+^) for BG505 SOSIP probes. Percentage of gated cells in their parental cell population is shown in red ([Figure 1C](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

###### 

Statistic properties of the BG505-specific B cell sorting and Ig cloning.

                                                                                        Guinea
  ------------------------------------------------------------------------------------- ------------
  Total PBMCs                                                                           10,050,000
  Total Lymphocytes                                                                     4,429,926
  Total Lymphocytes %                                                                   44.1
  Total single cells                                                                    4,272,286
  Total single cells %                                                                  96.4
  Total live cells                                                                      4,199,193
  Total live cells %                                                                    98.3
  Total IgG^hi^ IgM^lo^ class-switched B cell                                           76,545
  Total IgG^hi^ IgM^lo^ class-switched B cell %                                         1.82
  Total IgG^hi^ IgM^lo^ BG505 SOSIP dual + class-switched B cell                        81
  Total IgG^hi^ IgM^lo^ BG505 SOSIP dual + class-switched B cell %                      0.11
  Sorted cells                                                                          88
  Sorted cells with paired VH and VK/VL                                                 24
  Expressed mAbs                                                                        20
  Clonal lineage of expressed mAbs                                                      9
  BG505 SOSIP + mAbs (assessed by ELISA)                                                16
  Sorting precision \[(GP+mAbs/Expressed mAbs)^∗^100\], assessed by ELISA               80%
  BG505 SOSIP + mAbs (assessed by BLI)                                                  17
  Sorting precision \[(GP+mAbs/Expressed mAbs)^∗^100\], assessed by BLI                 85%
  Ag-specific mAbs (assessed by ELISA, BLI, and clonal lineage analysis)                20
  Precision of Ag-specific mAbs (assessed by ELISA, BLI, and clonal lineage analysis)   100%
                                                                                        

Guinea Pig Ig Gene-Specific Single Cell RT-PCR
----------------------------------------------

We first performed reverse transcription (RT) to convert mRNA to cDNA with the sorted single B cells. We thawed the cells in lysis buffer followed by the addition of 450 ng random hexamers (Gene Link), 2 μl 10 mM dNTP (Sigma), 200 U Superscript III (Invitrogen) to a 26 μl final reaction volume. The RT program was set as the following: 10 min at 42°C, 10 min at 25°C, 60 min at 50°C, 5 min at 94°C, followed by held at 4°C.

To amplify Ig encoding genes from the cDNA, we designed primers for semi-nested PCR reaction based on the guinea pig Ig gene segments recently identified ([@B7]; [Figure 2](#F2){ref-type="fig"} and [Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}). The 5′ forward primers were designed to anneal to the 5′ end of the framework 1 (FR1) regions in V-gene segments. The 3′ reverse primers are situated in the constant region, with the 3′ inner primers for the 2nd PCR closer to J genes than the 3′ outer primers for the 1st PCR reactions ([Figure 2C](#F2){ref-type="fig"}). The 1st PCR reaction was performed in a 50 μl reaction mixture consisting of 5 μl of cDNA, 5 μl of 10× PCR Buffer (Qiagen), 1 μl of 25 mM MgCl~2~ (Qiagen), 1 μl of 10 mM dNTPs (Sigma), 2 Unites of HotStar Taq Plus (Qiagen), 5 μl of 25 μM 5′ primer mixtures, and 1 μl of 25 μM 3′ outer primers. The 2nd PCR reaction mixture consisted of 2.5 μl of the same 5′ forward primer mixtures (25 μM) as in the 1st PCR with 0.5 μl of 25 μM 3′ inner primers as reverse primers ([Figure 2C](#F2){ref-type="fig"}), and 5 μl 5× Q-solution without MgCl~2~ in 25 μl of volume. All the 5′ primers used for each heavy (VH), lambda (VL), and kappa (VK) chain amplification were stored at 25 μM and mixed in equal volume prior to the PCR reactions. All semi-nested PCRs were incubated at 94°C for 5 min followed by 50 cycles of 94°C for 30 s, 50°C for 45 s, and 72°C for 1 min with a final elongation at 72°C for 10 min before cooling to 4°C. The PCR products were evaluated on 2% 96-well E Gels (Life Technologies). Wells with expected sizes approximately 500 and 420 bp for heavy/kappa chains and lambda chain, respectively, were identified followed by PCR product purification and sequencing using downstream 3′ inner primers. The PCR primers for heavy, lambda, and kappa chains are described in [Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}, respectively.

![Single cell RT-PCR to amplify antigen-specific guinea pig B cell IGH, IGL, and IGK transcripts. **(A)** Guinea pig heavy and light chain gene organization and primer design. Antibody repertoire diversity is primarily determined by the somatic recombination of variable (V), diversity (D), and joining (J) gene segments, followed by the random non-templated nucleotides insertions in the V-D-J or V-J hotspots. Numbers of functional V, D, and J gene segments identified for heavy and light chains are indicated. **(B)** Numbers of primers designed for VH, VK, and VL amplification. **(C)** Immunoglobulin gene amplification by semi-nested PCR from single cell cDNA resulted from random-hexamer primed reverse transcription. The 1st PCRs were performed with 5′ forward primer mixtures and 3′ reverse primers specific for the heavy- or light-chain constant regions. The 2nd PCRs were performed with the same set of 5′ primers and 3′ reverse primers specific for the constant regions more adjacent to the J gene segments. The 2nd PCR products were sequenced to determine the V and J primers for seamless cloning PCR. Cloning PCR products were assembled with antibody heavy and light chain expression vectors. **(D)** Representative 2% gel electrophoresis patterns of the 2nd PCR products of heavy chain (HC, ∼500 bp), kappa chain (KC, ∼500 bp), and lambda chain (LC, ∼420 bp). **(E)** Genetic analysis of the sorted Ag-specific B cells with paired heavy- and light-chains. (Left) Clonal lineage analysis of the sorted putative Ag-specific mAb variable sequences. N, total number of sorted cells; C, total number of clonal lineages, which is determined by the following criteria: B cell clones with the same Ig V, J gene usage and identical CDR3 length with CDR3 nucleotide sequence homology \>80% belong to the same clonal lineage and are likely derived from one naive B cell precursor. Each slice of the pie chart represents one clonal lineage. Clonal lineages (\#1, \#5, and \#7) with multiple members are displayed as exploded slices. (Right) Somatic hypermutation levels of the Ag-specific B cell Ig variable regions (VH and VK/VL) were calculated as percentage of nucleotide sequence divergence from germline V gene sequences.](fmicb-10-00672-g002){#F2}

###### 

Ig heavy PCR primer.

  Single cell PCR               Primer                Sequence (5′--3′)         V gene segment
  ----------------------------- --------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------------
  Heavy Chain Forward primers   5′GP_VH\#1            GAGGAGCAACTGGTGGAGTCC     VH3-157, VH3-139
                                5′GP_VH\#2            CAGTTGCAGCTGCAGGAGTCA     VH1-14
                                5′GP_VH\#3            CAGGTGCAGCTGCAGGAGTCG     VH1-120, VH1-115, VH1-58
                                5′GP_VH\#4            CAGGTGCAGCTGCAGGAGTTG     VH1-56
                                5′GP_VH\#5            GAAGTACAGCTCACACAATCT     VH3-184
                                5′GP_VH\#6            GAGGTGCAGCTCGTGGAGTCT     VH3-170, VH3-167
                                5′GP_VH\#7            CAGGTTCAGCTGCAGGAGTCG     VH1-66, VH1-75
                                5′GP_VH\#8            CAGGTTCAGCTGCAGGAGTCA     VH1-1
                                5′GP_VH\#9            GAGGAGCAGCTGGTAGAGTCC     VH3-63, VH3-3
                                5′GP_VH\#10           GAGGTGCAGCTGGTGGAGTCT     VH3-35
                                5′GP_VH\#11           GAGGTGCAGCTGATGGAGTCC     VH3-230
                                5′GP_VH\#12           CAGGTGCAGCTACAGGAGTCG     VH1-95
                                5′GP_VH\#13           GAAGAGCAGCTGGTGGAGTCT     VH3-80
                                5′GP_VH\#14           GAGCCGCAGCTGGTGGAGTCA     VH3-194
                                5′GP_VH\#15           GAAGTACAGCTCACACAGTCT     VH3-201
                                5′GP_VH\#16           GAAGTGCAGCTCGTGGAGTCC     VH3-262
                                5′GP_VH\#17           GAAGTGCAACTCGTGGAGTCC     VH3-126
                                5′GP_VH\#18           GGTGCAGCTGGTGGAGTCCGG     VH3-98
                                5′GP_VH\#19           GAGGTACAGCTCGTGGAATCT     VH3-282
                                5′GP_VH\#20           GACGTACAGCTCGTGGAGTCT     VH3-265
                                5′GP_VH\#21           GAGGAGCAACTGGTAGAGTCT     VH3-74
                                5′GP_VH\#22           GAGCCGCAGCTGGTAGAATCC     VH3-204
                                5′GP_VH\#23           GCGGAGCAGCTGGTGGAGTCC     VH3-189
                                5′GP_VH\#24           GAGGTGCAGCTGGTAGAGTCT     VH3-42, VH3-23, VH3-2
                                5′GP_VH\#25           GAGGTGCAGTTGGTAGAGTCT     VH3-9
                                5′GP_VH\#26           GATGAGCAACTGGTAGAGTCC     VH3-20
                                5′GP_VH\#27           GAGGTGCAGCTCATGGAGTCT     VH3-166
                                5′GP_VH\#28           CAGGTGCAGCTACAGGAGTCA     VH1-68, VH1-59
                                5′GP_VH\#29           GAGTTGCAGCTGGTGGAGTAC     VH3-222
                                5′GP_VH\#30           GAGGAGCAGGTGGTGGAGCCC     VH3-36, VH3-8
                                5′GP_VH\#31           GAGGTACAGCTCGTGGAGTCT     VH3-194
                                5′GP_VH\#32           CAGGTGAAGCTGCAGGAGTCA     VH2-67
                                5′GP_VH\#33           GAGCAGCAACTCGTGGAGTCC     VH3-255
                                5′GP_VH\#34           CAGCTGCAGCTGAAGGAGTCA     VH1-4
                                5′GP_VH\#35           CAAATGCAGCTGCAAGAGTCA     VH2-145
                                5′GP_VH\#36           CAGGTGCAGCTGCAGGAGTCC     VH1-215, VH1-209, VH1-84
                                5′GP_VH\#37           GAGGTGCTGCTGGTGGAGTCT     VH3-48
                                5′GP_VH\#38           CAGGTGCAGAAGCAGGAGTCA     VH2-70
                                5′GP_VH\#39           GAGGTGCAGCTGGTGGAGTCC     VH3-114
                                5′GP_VH\#40           GAGGTACAGCTCGTGGAGGCT     VH3-211
                                5′GP_VH\#41           CAAATGCAGCTGCAGGAGTCA     VH2-216
                                5′GP_VH\#42           AAGGTACGGCTGGTGGAGTCC     VH3-190
                                5′GP_VH\#43           CAGGTGCAGCTGCAAGAGTCG     VH1-140
                                5′GP_VH\#44           CAGGTTCAGCTGCAAGAGTCA     VH1-151
                                5′GP_VH\#45           CAGGTGCAGCTGCAGGAGTCA     VH2-239, VH1-171, VH1-156, VH1-101, VH1-77, VH2-160, VH2-94, VH2-86, VH2-54, VH2-43, VH2-35, VH2-28, VH2-27, VH2-17, VH2-7
                                5′GP_VH\#46           CAGGGGCAGCTGCAGGAGTCA     VH2-121, VH2-109
                                5′GP_VH\#47           GAGGAGCAGCTGGTGGAGTCC     VH3-229, VH3-186, VH3-185, VH3-183, VH3-51, VH3-24
                                5′GP_VH\#48           CAGATGCAGCTGCAGGAGTCA     VH1-91
                                5′GP_VH\#49           GAGGAGCAACTGGTAGAGTCC     VH3-150, VH3-102, VH3-89, VH3-46, VH3-37, VH3-30, VH3-176, VH3-135, VH3-80
                                5′GP_VH\#50           GAGGCGCAGCTGGTGGAATCC     VH3-197
                                5′GP_VH\#51           GAGGAGAAGCTGGTGGAGTCT     VH3-137
                                5′GP_VH\#52           GAGGAGCAGCTGGTGGAGTCT     VH3-287, VH3-271, VH3-104
                                                                                
  Reverse primers               3′C_gama_CH1_GP       GGTAGGTGTGCACTCCACTGGTC   Cγ (1st PCR)
                                3′IgG(Internal)\_GP   GCTCAGGGAAGTAGCCCTTGAC    Cγ (2nd PCR)
                                                                                

###### 

Ig lambda PCR primers.

  PCR                           Primer             Sequence (5′--3′)              V gene segment
  ----------------------------- ------------------ ------------------------------ ------------------------------------------------------------------------
  Lamda Chain Forward primers   5′GP_VL\#1         CAGCTTGTGCTGACTCAGTCACCCT      VL4-92
                                5′GP_VL\#2         TCCTATGTGCTGACACAGCCGTCTT      VL3-39
                                5′GP_VL\#3         TCCTATGTGCTCAAACAGCCACCTT      VL3-30
                                5′GP_VL\#4         CAGCCGGTGCTCACTCAACCACCCT      VL3-134
                                5′GP_VL\#5         CAGCCTGTGCTGACTCAGCTTCCCT      VL8-87
                                5′GP_VL\#6         TCCTATGTACTGACACAGCCATCTT      VL3-27
                                5′GP_VL\#7         CAGGAACTGGTGACTCAGGAACCCT      VL5-74
                                5′GP_VL\#8         TCTTACACCCTCACTCAACCTCCCT      VL3-55, VL3-31, VL3-47, VL3-41, VL3-9
                                5′GP_VL\#9         TCCTATGTATTCACACAGCCACCTT      VL3-6
                                5′GP_VL\#10        CAGCCTGTGCTGAAACAGTCACCCT      VL4-138, VL4-84, VL4-82
                                5′GP_VL\#11        CAGGTTGTGCTGACTCAGTCACCCT      VL4-80
                                5′GP_VL\#12        CAGACTTCAGTCACCCAGGAGCCAT      VL7-129
                                5′GP_VL\#13        CAGCCTGTGCTGACTCAGCTGCCCT      VL8-104, VL8-85
                                5′GP_VL\#14        CAGGCAGTGCTGAGTCAGCCGCCCT      VL1-125
                                5′GP_VL\#15        CAGGATCTGGTGACTCAGGAACCCT      VL5-79, VL5-78
                                5′GP_VL\#16        CTGGCTGTGGTAACTCAGGAATCTT      VL6-102
                                5′GP_VL\#17        TCGTATGTGCTGACGCAGCCATCTT      VL3-21
                                5′GP_VL\#18        TCCTATGTGCTGACACAGCCATCTT      VL3-4
                                5′GP_VL\#19        CAGTCTGGCCTAAGTCAGGAAGCTT      VL1-96
                                5′GP_VL\#20        TCCTATGTACTCACACAGCCACCCT      VL3-53
                                5′GP_VL\#21        AAGGCTGTGGTGACTCAGGAATCTT      VL6-115
                                5′GP_VL\#22        TCCTATGTACTCACACAGTCACCTT      VL3-24
                                5′GP_VL\#23        TCCTATGTGCTGACGCAGCCATCTT      VL3-50, VL3-34, VL3-32, VL3-16, VL3-48, VL3-45, VL3-42, VL3-13, VL3-10
                                5′GP_VL\#24        TCCTATGTACTCACACAGCCACCTT      VL3-52, VL3-29
                                5′GP_VL\#25        CAGGCTGTGGTGACTCAGGAACCTT      VL6-71
                                5′GP_VL\#26        CAGCTTGTGCTGACTCAGTCACCTT      VL4-121
                                5′GP_VL\#27        CAGAATGTAGCGACCCAGGTATCCT      VL5-106
                                5′GP_VL\#28        CAGACTGTGGTGACCCAGGTATTCT      VL5-122
                                5′GP_VL\#29        CAGGCAGTGCTGACTCAGCTGCCCT      VL1-95
                                5′GP_VL\#30        CAGGCAGTGCTGACTCAGCCGCCCT      VL1-109
                                5′GP_VL\#31        TCTTATATCTTGACACAGCCACCCT      VL3-19
                                5′GP_VL\#32        TCTTACATCTTGACACAGCCTCCCT      VL3-43_VL3-35
                                5′GP_VL\#33        CAGGCTGTGGTGACTCAGGAATCTT      VL6-132, VL6-98, VL6-69, VL6-68, VL6-116
                                5′GP_VL\#34        CAGGATCTGGTAACTCAGGAACCTT      VL5-99
                                5′GP_VL\#35        TCCTATGTGCTCACACAGCCACCTT      VL3-8
                                5′GP_VL\#36        CAGCCTGTAGTGACTCAACCACCCT      VL5-139
                                                                                  
  Reverse primers               3′\_C_LM_OUT1_GP   CACCACTGTGGCCTTGTTKTCCTGG      Cλ (1st PCR)
                                3′\_C_LM_OUT2_GP   CACCACTGTGGCCTTGTTTTCGTTG      Cλ (1st PCR)
                                3′XhoI_CL_Int_GP   CTCCTCACTCGAGGGYGGGAAYAGGCTG   Cλ (2nd PCR)
                                                                                  

###### 

Ig kappa PCR primers.

  PCR                           Primer             Sequence (5′--3′)           V gene segment
  ----------------------------- ------------------ --------------------------- ----------------------------------------------------------------------------------------------------------
  **IGK PCR primers**                                                          
  Kappa Chain Forward primers   5′GP_VK\#1         GACATCCAGATGACCCAGTCTCCAT   Vk1-142
                                5′GP_VK\#2         GACATTGTTATGACCCAGTCTACAG   Vk4-36
                                5′GP_VK\#3         GCATCCAGTTGACACAGCCTCCATC   Vk1-178
                                5′GP_VK\#4         GTCATCCAGATGATGCAGTATTCAT   Vk3-108
                                5′GP_VK\#5         GATATCCAGTTGACACAGCCTGCAT   Vk1-147, Vk1-58
                                5′GP_VK\#6         GACATTTTGATGACCCAGTCTCCAG   Vk4-37
                                5′GP_VK\#7         GAAATTCAGATGACACAAACTTCCT   Vk1-99
                                5′GP_VK\#8         GAAGTTGTGCTGACCCAGACTCCAC   Vk2-124
                                5′GP_VK\#9         GACATCCAGATGATCCAGTCACCAG   Vk1-133
                                5′GP_VK\#10        GACATCCAGATTACTCAGACTCCAT   Vk1-174
                                5′GP_VK\#11        GACATCCAGATGACTCAGACTCCAT   Vk1-280, Vk1-226, Vk1-55, Vk1-51, Vk1-47, Vk1-40, Vk1-15
                                5′GP_VK\#12        GACATCCAGATGACTCAGACTCCGT   Vk1-272
                                5′GP_VK\#13        GAAACCCTGCTGACTGAGACTCCAG   Vk3-25
                                5′GP_VK\#14        GACATCCAGTTGACGCAGCCTCCAT   Vk1-201
                                5′GP_VK\#15        GATGTTCTGATGACCCAGACCCCAC   Vk2-15
                                5′GP_VK\#16        GATGTAGTGATGACCCAGACTCCAC   Vk2-16
                                5′GP_VK\#17        GATACTCAGATGACTCAGTCTCCAT   Vk1-247
                                5′GP_VK\#18        GAAACCCTTCTGACACAGACCCCAG   Vk3-155
                                5′GP_VK\#19        GATGTTGTGGTGACCCAGACCCCAC   Vk2-51, Vk2-11
                                5′GP_VK\#20        GATATCCAGATGACTCAGGCTCCTT   Vk1-230
                                5′GP_VK\#21        GACATCCAGATGATTCAGACTCCAT   Vk1-21
                                5′GP_VK\#22        GACATTGTGATGACTCAGTCTCCAG   Vk4-28
                                5′GP_VK\#23        GACATCCAGTTAACACAGCCTCCAT   Vk1-211, Vk1-159
                                5′GP_VK\#24        GACATCCAGTTGACCCAGTCTCCAT   Vk1-246
                                5′GP_VK\#25        GACATTAGGATGACCCAGACCCCAC   Vk2-85
                                5′GP_VK\#26        GATGTTGTATTGACCCAAACCCCAC   Vk2-14
                                5′GP_VK\#27        GACATCCAGATGACCCAGTCACCAT   Vk1-190
                                5′GP_VK\#28        GACATTGTGATGACCCAGTCTCCAG   Vk4-70, Vk4-95, Vk4-45, Vk4-41, Vk4-39, Vk4-32, Vk4-29, Vk4-90, Vk4-83, Vk4-81
                                5′GP_VK\#29        GAAACCCTGTTGACCCAGACTCCAG   Vk3-170
                                5′GP_VK\#30        GATATCCAGTTGACACAGCCTCCAT   Vk1-152
                                5′GP_VK\#31        GACATTGTGATGACCCAGTCACCAG   Vk4-74
                                5′GP_VK\#32        GAAATTGTGATGACCCAGTCTCCAG   Vk4-77
                                5′GP_VK\#33        GACATCCCGATGACTCAGATTCCAT   Vk1-36
                                5′GP_VK\#34        GACATTCAGATGACCCAGTCTCCAT   Vk1-140, Vk1-65, Vk1-254
                                5′GP_VK\#35        GACATACAGATGACCCAGTGTCCAT   Vk1-234
                                5′GP_VK\#36        GACAATGTGGTGATCCAGTCTCCAG   Vk4-69
                                5′GP_VK\#37        GACATCCAGTTGACACAGCCTCCTT   Vk1-214
                                5′GP_VK\#38        GACATCCAGATGACCCAGTCTCAAT   Vk1-144
                                5′GP_VK\#39        GACACCCAGATGACCCAGTCTCCAT   Vk1-145
                                5′GP_VK\#40        GACATCCAGATGACTCAGACTGCAT   Vk1-59
                                5′GP_VK\#41        GACTTCCAGATGACCCAGTCACCAT   Vk1-219
                                5′GP_VK\#42        GACATCCAGTTGACACAGCCTCCAT   Vk1-242, Vk1-239
                                5′GP_VK\#43        GACATAGTGATGACCCAGACCCCAC   Vk2-10
                                5′GP_VK\#44        GATGTTGTGATGACCCAGACCGCAC   Vk2-7
                                5′GP_VK\#45        GACATCCGGATGACTCAGACTCCAT   Vk1-179
                                5′GP_VK\#46        GAAAAATTACTGACTAAGACTCCAG   Vk3-263
                                5′GP_VK\#47        GATATCCAGATGACTCAGGCTCCCT   Vk1-267
                                5′GP_VK\#48        GACATCCAATTGACACAGCCTGCAT   Vk1-279, Vk1-266, Vk1-29, Vk1-18, Vk1-1
                                5′GP_VK\#49        GAAACCCAGCTGACTCAGACTCCAG   Vk3-281, Vk3-60, Vk3-42
                                5′GP_VK\#50        GATATTGTGATGACACAGACCCCAC   Vk2-20
                                5′GP_VK\#51        GACATCCAGTTGACCCAGACTCCAG   Vk1-126
                                5′GP_VK\#52        GACATCCTATTAACCCAGCCTCCCT   Vk1-101
                                5′GP_VK\#53        CAAATTGTGCTCACCCAGACTCCAG   Vk5-57
                                5′GP_VK\#54        GATGTTTTGATGACCCAGACCCCAC   Vk2-22
                                5′GP_VK\#55        GAAATTGTGCTTACCCAGTCTCCAG   Vk5-105
                                5′GP_VK\#56        GATATCCAGTTGACCCAGTCTTCCT   Vk1-117
                                5′GP_VK\#57        GACATCAAATTGACTCAGCCAGCAT   Vk1-233
                                5′GP_VK\#58        GTGTAGGAAAAAACATCACTATTAC   Vk1-245
                                5′GP_VK\#59        GACATCCAGATGACTCAGACTCTCT   Vk1-153
                                5′GP_VK\#60        GACATCCAGTTGACCCAGTCTCCCT   Vk1-131, Vk1-115, Vk1-65
                                5′GP_VK\#61        GACCTTGTTATGACACAGTCTCCAG   Vk4-76
                                5′GP_VK\#62        GACATTCAGATGAGCCAGTCTCCAT   Vk1-184
                                5′GP_VK\#63        GACATCCAGTTGATGCAGCCTCCAT   Vk1-253
                                5′GP_VK\#64        GATGTTGTGATGACCCAGACCCCAC   Vk2-3
                                5′GP_VK\#65        GACATCCAACTGACACAACCTGCAT   Vk1-261, Vk1-203
                                5′GP_VK\#66        GACATCCAGATGACTCAGTCTCCCT   Vk1-130, Vk1-128
                                5′GP_VK\#67        GACATCCAAATGACTCAGGTTCCAT   Vk1-166
                                5′GP_VK\#68        GATGTTTTGTTGTCCCAGACCCCAC   Vk2-2
                                5′GP_VK\#69        GACATCCAGTTGACACAGCCTGCAT   Vk1-275, Vk1-271, Vk1-225, Vk1-54, Vk1-50, Vk1-46, Vk1-45, Vk1-39, Vk1-35, Vk1-24, Vk1-20, Vk1-14, Vk1-8
                                5′GP_VK\#70        GACATCCAGCTGACACAGCTTGCAT   Vk1-11
                                5′GP_VK\#71        GCGTTGCCCTGACACAGTCCCCAGC   Vk6-164
                                                                               
  Reverse primers               3′ Ck 156_OUT_GP   GTGTTGTCCTTGCTGTCCTGATC     Ck (1st PCR)
                                3′Ck_internal_GP   GTTCAGAGCCATCCACCTTCCAC     Ck (2nd PCR)
                                                                               

Single B Cell Ig Gene Sequence Analysis
---------------------------------------

Sequences of the semi-nested PCR products were initially analyzed by IMGT/High V-Quest ([@B1]) to define Ig gene structure, particularly the framework and CDR boundaries, using human Ig sequences as reference. The V(D)J sequences identified were further annotated by the stand-alone software IgBLAST ([@B35]) using previously annotated guinea pig germline sequences ([@B7]) as reference, which were annotated from guinea pig genome database^[1](#fn01){ref-type="fn"}^. Somatic hypermutation (SHM) level (Mut %) was calculated as the divergence of antibody VH/VL/VK sequences from the assigned germline sequences at nucleotide level. Clonal lineages were defined by the usage of V and J segments, and CDR3 homology (\>80% homology).

Cloning and Expression of Guinea Pig Monoclonal Antibodies in a Guinea Pig-Human Chimeric Form
----------------------------------------------------------------------------------------------

After sequence annotation, the VH/VK/VL amplicons from single cell RT-PCR were inserted into human IgG1 expression vectors ([@B28]) by seamless cloning as described next to form guinea pig-human chimeric mAbs. Amplicons were subjected to another round of PCR amplification (cloning PCR) using seamless cloning primers, which contain VH/VK/VL gene-specific regions and additional overhangs identical to the sequences in the expression vectors ([Figure 2C](#F2){ref-type="fig"}). The products of cloning PCR reactions were purified and inserted into expression vectors by seamless cloning. Seamless cloning primers designed for VH, VK, and VL amplification and cloning are summarized in [Figure 2C](#F2){ref-type="fig"} and [Tables 5](#T5){ref-type="table"}--[7](#T7){ref-type="table"}. The primers for each cloning PCR were selected based on germline V and J gene segment usage derived from the Ig gene sequence analysis. The cloning PCR reaction was performed in a total volume of 50 μl with high-fidelity DNA polymerase (Roche). The PCR reaction mixture consisted of 1 μl of template using the 2nd PCR product from the single cell RT-PCR reaction, 5 μl of 10× reaction buffer, 1 μl of 10 mM dNTPs, 1 μl of 25 μM of 5′ and 3′ cloning primers, 1 μl of high-fidelity DNA polymerase (3.5 Unit/μl, Roche) and nuclease-free water. The PCR program had an initial denaturation at 95°C for 3 min, followed by 20 cycles of 95°C for 30 s, 50°C for 30 s, and 68°C for 2 min. There was a final elongation step at 68°C for 8 min. The products were evaluated on 1% agarose gels before being assembled into their respective expression vectors containing human Igγ1H, Igκ1L, or Igλ2L constant regions described previously ([@B28]). The assembly (insertion) reactions were performed with GeneArt assembly enzyme mix (Invitrogen) per manufacturer's instructions.

###### 

Ig heavy cloning primers.

  Cloning PCR                   Primer                   Sequence (5′--3′)                                        V gene segment
  ----------------------------- ------------------------ -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  **IGH PCR primers**                                                                                             
  Heavy Chain Forward primers   SL_5′GP_VH\#1            tttctagtagcaactgcaaccggtgtacattctGAGGAGCAACTGGTGGAGTCC   VH3-157, VH3-139
                                SL_5′GP_VH\#2            tttctagtagcaactgcaaccggtgtacattctCAGTTGCAGCTGCAGGAGTCA   VH1-14
                                SL_5′GP_VH\#3            tttctagtagcaactgcaaccggtgtacattctCAGGTGCAGCTGCAGGAGTCG   VH1-120, VH1-115, VH1-58
                                SL_5′GP_VH\#4            tttctagtagcaactgcaaccggtgtacattctCAGGTGCAGCTGCAGGAGTTG   VH1-56
                                SL_5′GP_VH\#5            tttctagtagcaactgcaaccggtgtacattctGAAGTACAGCTCACACAATCT   VH3-184
                                SL_5′GP_VH\#6            tttctagtagcaactgcaaccggtgtacattctGAGGTGCAGCTCGTGGAGTCT   VH3-170, VH3-167
                                SL_5′GP_VH\#7            tttctagtagcaactgcaaccggtgtacattctCAGGTTCAGCTGCAGGAGTCG   VH1-66, VH1-75
                                SL_5′GP_VH\#8            tttctagtagcaactgcaaccggtgtacattctCAGGTTCAGCTGCAGGAGTCA   VH1-1
                                SL_5′GP_VH\#9            tttctagtagcaactgcaaccggtgtacattctGAGGAGCAGCTGGTAGAGTCC   VH3-63, VH3-3
                                SL_5′GP_VH\#10           tttctagtagcaactgcaaccggtgtacattctGAGGTGCAGCTGGTGGAGTCT   VH3-35
                                SL_5′GP_VH\#11           tttctagtagcaactgcaaccggtgtacattctGAGGTGCAGCTGATGGAGTCC   VH3-230
                                SL_5′GP_VH\#12           tttctagtagcaactgcaaccggtgtacattctCAGGTGCAGCTACAGGAGTCG   VH1-95
                                SL_5′GP_VH\#13           tttctagtagcaactgcaaccggtgtacattctGAAGAGCAGCTGGTGGAGTCT   VH3-80
                                SL_5′GP_VH\#14           tttctagtagcaactgcaaccggtgtacattctGAGCCGCAGCTGGTGGAGTCA   VH3-194
                                SL_5′GP_VH\#15           tttctagtagcaactgcaaccggtgtacattctGAAGTACAGCTCACACAGTCT   VH3-201
                                SL_5′GP_VH\#16           tttctagtagcaactgcaaccggtgtacattctGAAGTGCAGCTCGTGGAGTCC   VH3-262
                                SL_5′GP_VH\#17           tttctagtagcaactgcaaccggtgtacattctGAAGTGCAACTCGTGGAGTCC   VH3-126
                                SL_5′GP_VH\#18           tttctagtagcaactgcaaccggtgtacattctGGTGCAGCTGGTGGAGTCCGG   VH3-98
                                SL_5′GP_VH\#19           tttctagtagcaactgcaaccggtgtacattctGAGGTACAGCTCGTGGAATCT   VH3-282
                                SL_5′GP_VH\#20           tttctagtagcaactgcaaccggtgtacattctGACGTACAGCTCGTGGAGTCT   VH3-265
                                SL_5′GP_VH\#21           tttctagtagcaactgcaaccggtgtacattctGAGGAGCAACTGGTAGAGTCT   VH3-74
                                SL_5′GP_VH\#22           tttctagtagcaactgcaaccggtgtacattctGAGCCGCAGCTGGTAGAATCC   VH3-204
                                SL_5′GP_VH\#23           tttctagtagcaactgcaaccggtgtacattctGCGGAGCAGCTGGTGGAGTCC   VH3-189
                                SL_5′GP_VH\#24           tttctagtagcaactgcaaccggtgtacattctGAGGTGCAGCTGGTAGAGTCT   VH3-42, VH3-23, VH3-2
                                SL_5′GP_VH\#25           tttctagtagcaactgcaaccggtgtacattctGAGGTGCAGTTGGTAGAGTCT   VH3-9
                                SL_5′GP_VH\#26           tttctagtagcaactgcaaccggtgtacattctGATGAGCAACTGGTAGAGTCC   VH3-20
                                SL_5′GP_VH\#27           tttctagtagcaactgcaaccggtgtacattctGAGGTGCAGCTCATGGAGTCT   VH3-166
                                SL_5′GP_VH\#28           tttctagtagcaactgcaaccggtgtacattctCAGGTGCAGCTACAGGAGTCA   VH1-68, VH1-59
                                SL_5′GP_VH\#29           tttctagtagcaactgcaaccggtgtacattctGAGTTGCAGCTGGTGGAGTAC   VH3-222
                                SL_5′GP_VH\#30           tttctagtagcaactgcaaccggtgtacattctGAGGAGCAGGTGGTGGAGCCC   VH3-36, VH3-8
                                SL_5′GP_VH\#31           tttctagtagcaactgcaaccggtgtacattctGAGGTACAGCTCGTGGAGTCT   VH3-194
                                SL_5′GP_VH\#32           tttctagtagcaactgcaaccggtgtacattctCAGGTGAAGCTGCAGGAGTCA   VH2-67
                                SL_5′GP_VH\#33           tttctagtagcaactgcaaccggtgtacattctGAGCAGCAACTCGTGGAGTCC   VH3-255
                                SL_5′GP_VH\#34           tttctagtagcaactgcaaccggtgtacattctCAGCTGCAGCTGAAGGAGTCA   VH1-4
                                SL_5′GP_VH\#35           tttctagtagcaactgcaaccggtgtacattctCAAATGCAGCTGCAAGAGTCA   VH2-145
                                SL_5′GP_VH\#36           tttctagtagcaactgcaaccggtgtacattctCAGGTGCAGCTGCAGGAGTCC   VH1-215, VH1-209, VH1-84
                                SL_5′GP_VH\#37           tttctagtagcaactgcaaccggtgtacattctGAGGTGCTGCTGGTGGAGTCT   VH3-48
                                SL_5′GP_VH\#38           tttctagtagcaactgcaaccggtgtacattctCAGGTGCAGAAGCAGGAGTCA   VH2-70
                                SL_5′GP_VH\#39           tttctagtagcaactgcaaccggtgtacattctGAGGTGCAGCTGGTGGAGTCC   VH3-114
                                SL_5′GP_VH\#40           tttctagtagcaactgcaaccggtgtacattctGAGGTACAGCTCGTGGAGGCT   VH3-211
                                SL_5′GP_VH\#41           tttctagtagcaactgcaaccggtgtacattctCAAATGCAGCTGCAGGAGTCA   VH2-216
                                SL_5′GP_VH\#42           tttctagtagcaactgcaaccggtgtacattctAAGGTACGGCTGGTGGAGTCC   VH3-190
                                SL_5′GP_VH\#43           tttctagtagcaactgcaaccggtgtacattctCAGGTGCAGCTGCAAGAGTCG   VH1-140
                                SL_5′GP_VH\#44           tttctagtagcaactgcaaccggtgtacattctCAGGTTCAGCTGCAAGAGTCA   VH1-151
                                SL_5′GP_VH\#45           tttctagtagcaactgcaaccggtgtacattctCAGGTGCAGCTGCAGGAGTCA   VH2-239, VH1-171, VH1-156, VH1-101, VH1-77, VH2-160, VH2-94, VH2-86, VH2-54, VH2-43, VH2-35, VH2-28, VH2-27, VH2-17, VH2-7
                                SL_5′GP_VH\#46           tttctagtagcaactgcaaccggtgtacattctCAGGGGCAGCTGCAGGAGTCA   VH2-121, VH2-109
                                SL_5′GP_VH\#47           tttctagtagcaactgcaaccggtgtacattctGAGGAGCAGCTGGTGGAGTCC   VH3-229, VH3-186, VH3-185, VH3-183, VH3-51, VH3-24
                                SL_5′GP_VH\#48           tttctagtagcaactgcaaccggtgtacattctCAGATGCAGCTGCAGGAGTCA   VH1-91
                                SL_5′GP_VH\#49           tttctagtagcaactgcaaccggtgtacattctGAGGAGCAACTGGTAGAGTCC   VH3-150, VH3-102, VH3-89, VH3-46, VH3-37, VH3-30, VH3-176, VH3-135, VH3-80
                                SL_5′GP_VH\#50           tttctagtagcaactgcaaccggtgtacattctGAGGCGCAGCTGGTGGAATCC   VH3-197
                                SL_5′GP_VH\#51           tttctagtagcaactgcaaccggtgtacattctGAGGAGAAGCTGGTGGAGTCT   VH3-137
                                SL_5′GP_VH\#52           tttctagtagcaactgcaaccggtgtacattctGAGGAGCAGCTGGTGGAGTCT   VH3-287, VH3-271, VH3-104
                                                                                                                  
  Reverse primers               3′ *Sal*I JH 1_GP        agaccgatgggcccttggtcgacGCTGACGTGACGGTGACTGAG             JH 1
                                3′ *Sal*I JH 2_4\_6_GP   agaccgatgggcccttggtcgacGCTGAGGAGACGGTGACCAG              JH 2, JH 4, JH6
                                3′ *Sal*I JH 3_GP        agaccgatgggcccttggtcgacGCTGAGGAGATAGTGACCAG              JH 3
                                3′ *Sal*I JH 5_GP        agaccgatgggcccttggtcgacGCTGAGGAGACGGTGACCGA              JH 5
                                                                                                                  

###### 

Ig lambda cloning primers.

  Cloning PCR                   Primer                   Sequence (5′--3′)                                                                     V gene segment
  ----------------------------- ------------------------ ------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  **IGL PCR primers**                                                                                                                          
  Lamda Chain Forward primers   SL_5′GP_VL\#1            tttctagtagcaactgcaaccggttctctctcgCAGCTTGTGCTGACTCAGTCACCCT                            VL4-92
                                SL_5′GP_VL\#2            tttctagtagcaactgcaaccggttctctctcgTCCTATGTGCTGACACAGCCGTCTT                            VL3-39
                                SL_5′GP_VL\#3            tttctagtagcaactgcaaccggttctctctcgTCCTATGTGCTCAAACAGCCACCTT                            VL3-30
                                SL_5′GP_VL\#4            tttctagtagcaactgcaaccggttctctctcgCAGCCGGTGCTCACTCAACCACCCT                            VL3-134
                                SL_5′GP_VL\#5            tttctagtagcaactgcaaccggttctctctcgCAGCCTGTGCTGACTCAGCTTCCCT                            VL8-87
                                SL_5′GP_VL\#6            tttctagtagcaactgcaaccggttctctctcgTCCTATGTACTGACACAGCCATCTT                            VL3-27
                                SL_5′GP_VL\#7            tttctagtagcaactgcaaccggttctctctcgCAGGAACTGGTGACTCAGGAACCCT                            VL5-74
                                SL_5′GP_VL\#8            tttctagtagcaactgcaaccggttctctctcgTCTTACACCCTCACTCAACCTCCCT                            VL3-55, VL3-31, VL3-47, VL3-41, VL3-9
                                SL_5′GP_VL\#9            tttctagtagcaactgcaaccggttctctctcgTCCTATGTATTCACACAGCCACCTT                            VL3-6
                                SL_5′GP_VL\#10           tttctagtagcaactgcaaccggttctctctcgCAGCCTGTGCTGAAACAGTCACCCT                            VL4-138, VL4-84, VL4-82
                                SL_5′GP_VL\#11           tttctagtagcaactgcaaccggttctctctcgCAGGTTGTGCTGACTCAGTCACCCT                            VL4-80
                                SL_5′GP_VL\#12           tttctagtagcaactgcaaccggttctctctcgCAGACTTCAGTCACCCAGGAGCCAT                            VL7-129
                                SL_5′GP_VL\#13           tttctagtagcaactgcaaccggttctctctcgCAGCCTGTGCTGACTCAGCTGCCCT                            VL8-104, VL8-85
                                SL_5′GP_VL\#14           tttctagtagcaactgcaaccggttctctctcgCAGGCAGTGCTGAGTCAGCCGCCCT                            VL1-125
                                SL_5′GP_VL\#15           tttctagtagcaactgcaaccggttctctctcgCAGGATCTGGTGACTCAGGAACCCT                            VL5-79, VL5-78
                                SL_5′GP_VL\#16           tttctagtagcaactgcaaccggttctctctcgCTGGCTGTGGTAACTCAGGAATCTT                            VL6-102
                                SL_5′GP_VL\#17           tttctagtagcaactgcaaccggttctctctcgTCGTATGTGCTGACGCAGCCATCTT                            VL3-21
                                SL_5′GP_VL\#18           tttctagtagcaactgcaaccggttctctctcgTCCTATGTGCTGACACAGCCATCTT                            VL3-4
                                SL_5′GP_VL\#19           tttctagtagcaactgcaaccggttctctctcgCAGTCTGGCCTAAGTCAGGAAGCTT                            VL1-96
                                SL_5′GP_VL\#20           tttctagtagcaactgcaaccggttctctctcgTCCTATGTACTCACACAGCCACCCT                            VL3-53
                                SL_5′GP_VL\#21           tttctagtagcaactgcaaccggttctctctcgAAGGCTGTGGTGACTCAGGAATCTT                            VL6-115
                                SL_5′GP_VL\#22           tttctagtagcaactgcaaccggttctctctcgTCCTATGTACTCACACAGTCACCTT                            VL3-24
                                SL_5′GP_VL\#23           tttctagtagcaactgcaaccggttctctctcgTCCTATGTGCTGACGCAGCCATCTT                            VL3-50, VL3-34, VL3-32, VL3-16, VL3-48, VL3-45, VL3-42, VL3-13, VL3-10
                                SL_5′GP_VL\#24           tttctagtagcaactgcaaccggttctctctcgTCCTATGTACTCACACAGCCACCTT                            VL3-52, VL3-29
                                SL_5′GP_VL\#25           tttctagtagcaactgcaaccggttctctctcgCAGGCTGTGGTGACTCAGGAACCTT                            VL6-71
                                SL_5′GP_VL\#26           tttctagtagcaactgcaaccggttctctctcgCAGCTTGTGCTGACTCAGTCACCTT                            VL4-121
                                SL_5′GP_VL\#27           tttctagtagcaactgcaaccggttctctctcgCAGAATGTAGCGACCCAGGTATCCT                            VL5-106
                                SL_5′GP_VL\#28           tttctagtagcaactgcaaccggttctctctcgCAGACTGTGGTGACCCAGGTATTCT                            VL5-122
                                SL_5′GP_VL\#29           tttctagtagcaactgcaaccggttctctctcgCAGGCAGTGCTGACTCAGCTGCCCT                            VL1-95
                                SL_5′GP_VL\#30           tttctagtagcaactgcaaccggttctctctcgCAGGCAGTGCTGACTCAGCCGCCCT                            VL1-109
                                SL_5′GP_VL\#31           tttctagtagcaactgcaaccggttctctctcgTCTTATATCTTGACACAGCCACCCT                            VL3-19
                                SL_5′GP_VL\#32           tttctagtagcaactgcaaccggttctctctcgTCTTACATCTTGACACAGCCTCCCT                            VL3-43_VL3-35
                                SL_5′GP_VL\#33           tttctagtagcaactgcaaccggttctctctcgCAGGCTGTGGTGACTCAGGAATCTT                            VL6-132, VL6-98, VL6-69, VL6-68, VL6-116
                                SL_5′GP_VL\#34           tttctagtagcaactgcaaccggttctctctcgCAGGATCTGGTAACTCAGGAACCTT                            VL5-99
                                SL_5′GP_VL\#35           tttctagtagcaactgcaaccggttctctctcgTCCTATGTGCTCACACAGCCACCTT                            VL3-8
                                SL_5′GP_VL\#36           tttctagtagcaactgcaaccggttctctctcgCAGCCTGTAGTGACTCAACCACCCT                            VL5-139
  Reverse primers               3_GP\_*Xho*I_JL_1\_4_7   ggcttgaagctcctcactcgagggcgggaacagagtgaccaagggggaagccttgggctgaccg AGGACGGTCAGCTTGGTG   JL1, JL4, JL7
                                3_GP\_*Xho*I_JL_2\_5_9   ggcttgaagctcctcactcgagggcgggaacagagtgaccaagggggaagccttgggctgaccg AGGACCGTCAGCCTGGTT   JL2, JL5, JL6
                                3_GP\_*Xho*I_JL3_6\_10   ggcttgaagctcctcactcgagggcgggaacagagtgaccaagggggaagccttgggctgaccg AGGACGGTCAGCTTGGTT   JL3, JL6, JL10
                                3_GP\_*Xho*I_JL8         ggcttgaagctcctcactcgagggcgggaacagagtgaccaagggggaagccttgggctgaccg AGGACTGTCAGGTCGGTT   JL8
                                3_GP\_*Xho*I_JL11        ggcttgaagctcctcactcgagggcgggaacagagtgaccaagggggaagccttgggctgaccg AGGACGGTCACCTTGGTC   JL11
                                                                                                                                               

###### 

Ig kappa cloning primers.

  Cloning PCR                   Primer                     Sequence (5′--3′)                                            V gene segment
  ----------------------------- -------------------------- ------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------
  **IGK PCR primers**                                                                                                   
  Kappa Chain Forward primers   SL_5′GP_VK\#1              tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGACCCAGTCTCCAT   Vk1-142
                                SL_5′GP_VK\#2              tttctagtagcaactgcaaccggtgtacattctGACATTGTTATGACCCAGTCTACAG   Vk4-36
                                SL_5′GP_VK\#3              tttctagtagcaactgcaaccggtgtacattctGCATCCAGTTGACACAGCCTCCATC   Vk1-178
                                SL_5′GP_VK\#4              tttctagtagcaactgcaaccggtgtacattctGTCATCCAGATGATGCAGTATTCAT   Vk3-108
                                SL_5′GP_VK\#5              tttctagtagcaactgcaaccggtgtacattctGATATCCAGTTGACACAGCCTGCAT   Vk1-147, Vk1-58
                                SL_5′GP_VK\#6              tttctagtagcaactgcaaccggtgtacattctGACATTTTGATGACCCAGTCTCCAG   Vk4-37
                                SL_5′GP_VK\#7              tttctagtagcaactgcaaccggtgtacattctGAAATTCAGATGACACAAACTTCCT   Vk1-99
                                SL_5′GP_VK\#8              tttctagtagcaactgcaaccggtgtacattctGAAGTTGTGCTGACCCAGACTCCAC   Vk2-124
                                SL_5′GP_VK\#9              tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGATCCAGTCACCAG   Vk1-133
                                SL_5′GP_VK\#10             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATTACTCAGACTCCAT   Vk1-174
                                SL_5′GP_VK\#11             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGACTCAGACTCCAT   Vk1-280, Vk1-226, Vk1-55, Vk1-51, Vk1-47, Vk1-40, Vk1-15
                                SL_5′GP_VK\#12             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGACTCAGACTCCGT   Vk1-272
                                SL_5′GP_VK\#13             tttctagtagcaactgcaaccggtgtacattctGAAACCCTGCTGACTGAGACTCCAG   Vk3-25
                                SL_5′GP_VK\#14             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTGACGCAGCCTCCAT   Vk1-201
                                SL_5′GP_VK\#15             tttctagtagcaactgcaaccggtgtacattctGATGTTCTGATGACCCAGACCCCAC   Vk2-15
                                SL_5′GP_VK\#16             tttctagtagcaactgcaaccggtgtacattctGATGTAGTGATGACCCAGACTCCAC   Vk2-16
                                SL_5′GP_VK\#17             tttctagtagcaactgcaaccggtgtacattctGATACTCAGATGACTCAGTCTCCAT   Vk1-247
                                SL_5′GP_VK\#18             tttctagtagcaactgcaaccggtgtacattctGAAACCCTTCTGACACAGACCCCAG   Vk3-155
                                SL_5′GP_VK\#19             tttctagtagcaactgcaaccggtgtacattctGATGTTGTGGTGACCCAGACCCCAC   Vk2-51, Vk2-11
                                SL_5′GP_VK\#20             tttctagtagcaactgcaaccggtgtacattctGATATCCAGATGACTCAGGCTCCTT   Vk1-230
                                SL_5′GP_VK\#21             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGATTCAGACTCCAT   Vk1-21
                                SL_5′GP_VK\#22             tttctagtagcaactgcaaccggtgtacattctGACATTGTGATGACTCAGTCTCCAG   Vk4-28
                                SL_5′GP_VK\#23             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTAACACAGCCTCCAT   Vk1-211, Vk1-159
                                SL_5′GP_VK\#24             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTGACCCAGTCTCCAT   Vk1-246
                                SL_5′GP_VK\#25             tttctagtagcaactgcaaccggtgtacattctGACATTAGGATGACCCAGACCCCAC   Vk2-85
                                SL_5′GP_VK\#26             tttctagtagcaactgcaaccggtgtacattctGATGTTGTATTGACCCAAACCCCAC   Vk2-14
                                SL_5′GP_VK\#27             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGACCCAGTCACCAT   Vk1-190
                                SL_5′GP_VK\#28             tttctagtagcaactgcaaccggtgtacattctGACATTGTGATGACCCAGTCTCCAG   Vk4-70, Vk4-95, Vk4-45, Vk4-41, Vk4-39, Vk4-32, Vk4-29, Vk4-90, Vk4-83, Vk4-81
                                SL_5′GP_VK\#29             tttctagtagcaactgcaaccggtgtacattctGAAACCCTGTTGACCCAGACTCCAG   Vk3-170
                                SL_5′GP_VK\#30             tttctagtagcaactgcaaccggtgtacattctGATATCCAGTTGACACAGCCTCCAT   Vk1-152
                                SL_5′GP_VK\#31             tttctagtagcaactgcaaccggtgtacattctGACATTGTGATGACCCAGTCACCAG   Vk4-74
                                SL_5′GP_VK\#32             tttctagtagcaactgcaaccggtgtacattctGAAATTGTGATGACCCAGTCTCCAG   Vk4-77
                                SL_5′GP_VK\#33             tttctagtagcaactgcaaccggtgtacattctGACATCCCGATGACTCAGATTCCAT   Vk1-36
                                SL_5′GP_VK\#34             tttctagtagcaactgcaaccggtgtacattctGACATTCAGATGACCCAGTCTCCAT   Vk1-140, Vk1-65, Vk1-254
                                SL_5′GP_VK\#35             tttctagtagcaactgcaaccggtgtacattctGACATACAGATGACCCAGTGTCCAT   Vk1-234
                                SL_5′GP_VK\#36             tttctagtagcaactgcaaccggtgtacattctGACAATGTGGTGATCCAGTCTCCAG   Vk4-69
                                SL_5′GP_VK\#37             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTGACACAGCCTCCTT   Vk1-214
                                SL_5′GP_VK\#38             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGACCCAGTCTCAAT   Vk1-144
                                SL_5′GP_VK\#39             tttctagtagcaactgcaaccggtgtacattctGACACCCAGATGACCCAGTCTCCAT   Vk1-145
                                SL_5′GP_VK\#40             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGACTCAGACTGCAT   Vk1-59
                                SL_5′GP_VK\#41             tttctagtagcaactgcaaccggtgtacattctGACTTCCAGATGACCCAGTCACCAT   Vk1-219
                                SL_5′GP_VK\#42             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTGACACAGCCTCCAT   Vk1-242, Vk1-239
                                SL_5′GP_VK\#43             tttctagtagcaactgcaaccggtgtacattctGACATAGTGATGACCCAGACCCCAC   Vk2-10
                                SL_5′GP_VK\#44             tttctagtagcaactgcaaccggtgtacattctGATGTTGTGATGACCCAGACCGCAC   Vk2-7
                                SL_5′GP_VK\#45             tttctagtagcaactgcaaccggtgtacattctGACATCCGGATGACTCAGACTCCAT   Vk1-179
                                SL_5′GP_VK\#46             tttctagtagcaactgcaaccggtgtacattctGAAAAATTACTGACTAAGACTCCAG   Vk3-263
                                SL_5′GP_VK\#47             tttctagtagcaactgcaaccggtgtacattctGATATCCAGATGACTCAGGCTCCCT   Vk1-267
                                SL_5′GP_VK\#48             tttctagtagcaactgcaaccggtgtacattctGACATCCAATTGACACAGCCTGCAT   Vk1-279, Vk1-266, Vk1-29, Vk1-18, Vk1-1
                                SL_5′GP_VK\#49             tttctagtagcaactgcaaccggtgtacattctGAAACCCAGCTGACTCAGACTCCAG   Vk3-281_Vk3-60_Vk3-42
                                SL_5′GP_VK\#50             tttctagtagcaactgcaaccggtgtacattctGATATTGTGATGACACAGACCCCAC   Vk2-20
                                SL_5′GP_VK\#51             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTGACCCAGACTCCAG   Vk1-126
                                SL_5′GP_VK\#52             tttctagtagcaactgcaaccggtgtacattctGACATCCTATTAACCCAGCCTCCCT   Vk1-101
                                SL_5′GP_VK\#53             tttctagtagcaactgcaaccggtgtacattctCAAATTGTGCTCACCCAGACTCCAG   Vk5-57
                                SL_5′GP_VK\#54             tttctagtagcaactgcaaccggtgtacattctGATGTTTTGATGACCCAGACCCCAC   Vk2-22
                                SL_5′GP_VK\#55             tttctagtagcaactgcaaccggtgtacattctGAAATTGTGCTTACCCAGTCTCCAG   Vk5-105
                                SL_5′GP_VK\#56             tttctagtagcaactgcaaccggtgtacattctGATATCCAGTTGACCCAGTCTTCCT   Vk1-117
                                SL_5′GP_VK\#57             tttctagtagcaactgcaaccggtgtacattctGACATCAAATTGACTCAGCCAGCAT   Vk1-233
                                SL_5′GP_VK\#58             tttctagtagcaactgcaaccggtgtacattctGTGTAGGAAAAAACATCACTATTAC   Vk1-245
                                SL_5′GP_VK\#59             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGACTCAGACTCTCT   Vk1-153
                                SL_5′GP_VK\#60             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTGACCCAGTCTCCCT   Vk1-131, Vk1-115, Vk1-65
                                SL_5′GP_VK\#61             tttctagtagcaactgcaaccggtgtacattctGACCTTGTTATGACACAGTCTCCAG   Vk4-76
                                SL_5′GP_VK\#62             tttctagtagcaactgcaaccggtgtacattctGACATTCAGATGAGCCAGTCTCCAT   Vk1-184
                                SL_5′GP_VK\#63             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTGATGCAGCCTCCAT   Vk1-253
                                SL_5′GP_VK\#64             tttctagtagcaactgcaaccggtgtacattctGATGTTGTGATGACCCAGACCCCAC   Vk2-3
                                SL_5′GP_VK\#65             tttctagtagcaactgcaaccggtgtacattctGACATCCAACTGACACAACCTGCAT   Vk1-261, Vk1-203
                                SL_5′GP_VK\#66             tttctagtagcaactgcaaccggtgtacattctGACATCCAGATGACTCAGTCTCCCT   Vk1-130, Vk1-128
                                SL_5′GP_VK\#67             tttctagtagcaactgcaaccggtgtacattctGACATCCAAATGACTCAGGTTCCAT   Vk1-166
                                SL_5′GP_VK\#68             tttctagtagcaactgcaaccggtgtacattctGATGTTTTGTTGTCCCAGACCCCAC   Vk2-2
                                SL_5′GP_VK\#69             tttctagtagcaactgcaaccggtgtacattctGACATCCAGTTGACACAGCCTGCAT   Vk1-275, Vk1-271, Vk1-225, Vk1-54, Vk1-50, Vk1-46, Vk1-45, Vk1-39, Vk1-35, Vk1-24, Vk1-20, Vk1-14, Vk1-8
                                SL_5′GP_VK\#70             tttctagtagcaactgcaaccggtgtacattctGACATCCAGCTGACACAGCTTGCAT   Vk1-11
                                SL_5′GP_VK\#71             tttctagtagcaactgcaaccggtgtacattctGCGTTGCCCTGACACAGTCCCCAGC   Vk6-164
  Reverse primers               3′ *Bsi*WI Jk_1\_2_3\_GP   cagatggtgcagccaccgtacgTTTGATTTCCAGCTTGGTC                    JK 1, JK 2, JK 3
                                                                                                                        

For antibody expression, equal amount of heavy and light chain expression vectors containing the paired VH/VK/VL amplicons were transfected into 293F cells with 293fectin transfection reagent (Life Technologies) as previously described ([@B32]). For a typical transfection reaction, 12.5 μg of each of the VH/VK/VL expression vectors, prepared from 50 ml *E. coli* DH5α cultures, were used to transfect 50 million 293F cells in 50 ml volume. Supernatants were harvested 4 days post-transfection, followed by antibody purification with Protein A Sepharose columns (GE Healthcare). Thus, each guinea pig mAb was expressed as a chimeric mAb with the variable regions (VH/VK or VL) derived from guinea pig and the constant regions from human.

mAb Binding Analysis by Enzyme-Linked Immunosorbent Assay (ELISA)
-----------------------------------------------------------------

The binding specificity of the guinea pig mAbs recovered from single B cells was initially tested with the sorting probe, BG505 SOSIP trimer, and V3 peptides derived from BG505 V3 region (CTRPNNNTRKSIRIGPGQAFYATGDIIGDIRQAHC) and JR-FL (CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC) V3 region by ELISA assay. MaxiSorp 96-well plates (Nunc, Thermo Fisher Scientific) were coated with a mouse anti-His tag mAb (R&D Systems, MAB050) at 2 μg/ml in 100 μl of phosphate buffered saline (PBS) at 4°C overnight. After incubating with blocking buffer (PBS containing 5% FBS/2% non-fat milk) for 1 h at 37°C, 2 μg/ml of BG505 SOSIP trimers were added into each well and incubated for 1 h at room temperature. Subsequently, guinea pig mAbs were added in fivefold serial dilutions starting at 50 μg/ml and incubated for 1 h at room temperature. After wash, secondary HRP-conjugated anti-human IgG (Jackson ImmunoResearch) diluted at 1:10,000 in PBS/0.05% Tween 20 was added and incubated for 1 h at room temperature. The signal was developed by adding 100 μl of TMB substrate (Life Technologies) and incubation for 5 min followed by the addition of 100 μl of 1 N sulfuric acid to stop the reactions. The optical density (OD) of each well was measured at 450 nm to quantify binding activity. Between each incubation step, the plates were washed extensively with PBS supplemented with 0.05% Tween 20. The V3 peptides were coated at 2 μg/ml in 100 μl PBS at 4°C overnight, followed by the blocking, binding, washing, and detection procedures as stated above.

mAb Binding Analysis by BioLayer Interferometry (BLI) Assay
-----------------------------------------------------------

The binding activity and kinetics of selected mAbs to BG505 SOSIP trimer were further assessed by BLI assay via an Octet RED96 system (ForteBio) following the manufacturer's instruction as previously described ([@B32]). Octet Analysis version 9.0 software was used for data analysis. The guinea pig mAbs bearing the human IgG constant regions were initially captured by anti-human IgG Fc biosensors, followed by immersing into: (1) analyte wells containing BG505 SOSIP trimer in twofold dilution series in binding buffer (PBS/0.05% Tween 20/0.1% BSA) starting from 1000 to 250 nM to assess association rate (on-rate, *k*~on~), and subsequently (2) wells containing binding buffer to assess dissociation rate (off-rate, *k*~off~). Binding affinity constants (dissociation constant, *K*~D~) were determined as *k*~off~/*k*~on~.

HIV-1 Neutralization Assays
---------------------------

Antibody/serum neutralization assays were performed in a single round of infection using HIV-1 Env-pseudoviruses and TZM-bl target cells, as previously described ([@B13]). Antibodies (starting at 50 μg/ml) and serum (starting at 10-fold dilution) were diluted in fivefold series to assess neutralization activity. Neutralization curves were fitted by nonlinear regression using a five-parameter hill slope equation. The IC~50~ (or ID~50~) values of each antibody (or serum) were determined as the concentration (or dilution) of antibody (or serum) required to inhibit infection by 50%.

Results
=======

Guinea Pig Ag-Specific B Cell Sorting
-------------------------------------

To analyze B cell response in guinea pigs at the clonal level, we developed this antigen-specific single B cell sorting and mAb isolation method ([Figure 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). To evaluate the feasibility of this method, we first sorted HIV-1 Env-specific single B cells by FACS from PBMCs of animal 1567, which displayed potent serum neutralization against the autologous tier 2 virus BG505 and tier 1 isolate ZM109 ([Figure 1A,B](#F1){ref-type="fig"}). We selected animal 1567 for this study as its serum represents the overall virus neutralization profiles of this group, although this serum did not display the highest BG505 neutralization titer within the same group. Class-switched B cells with high level of surface IgG expression profile (IgG^hi^) were distinguished by sequential gating for lymphocytes, single cells, live cells (Aqua blue^-^), and cells with high/low signal for IgG and IgM, respectively (IgG^hi^ IgM^lo^) ([Figure 1C](#F1){ref-type="fig"}). Statistically, from 10 million PBMCs, 4.4 million cells were identified as lymphocytes, and 4.3 million lymphocytes were gated as singlet cells ([Figure 1C](#F1){ref-type="fig"}). Live cells, accounting for 98.3% of the singlet cells were identified with the negative Aqua Blue binding phenotype. 76,545 IgG^hi^ IgM^lo^ B cells were further determined among the live cells at the frequency of 1.82%, based on the fluorescent signals of anti-guinea pig IgM-FITC and anti-guinea pig IgG-Alexa Fluor 594 ([Figure 1C](#F1){ref-type="fig"}). Subsequently, we identified 88 Env-specific B cells (0.11% of IgG^hi^ IgM^lo^ B cells) with the phenotype of IgG^hi^ IgM^lo^/BG505 SOSIP dual^+^ (PE^+^APC^+^) ([Figure 1C](#F1){ref-type="fig"}), which were gated and sorted at single cell density into a 96-well PCR plate for downstream single cell IgG RT-PCR reactions ([Table 1](#T1){ref-type="table"}).

Guinea Pig Ig Heavy/Light Chain Amplification
---------------------------------------------

We performed RT-PCR to recover the variable region of heavy/light chain (VH/VK/VL) encoding genes of the sorted Ag-specific guinea pig B cells ([Figure 2](#F2){ref-type="fig"}). The cDNA of each single cell was synthesized by reverse transcription primed by random hexamers. To efficiently amplify Ig genes from cDNA, we developed a semi-nested PCR strategy. All the primers were designed based on the recently annotated guinea pig Ig loci ([@B7]). From the guinea pig genome sequence annotation study ([@B7]), 94 VH, 40 DH, and 6 JH gene segments were identified as functional heavy chain genes ([Figure 2A](#F2){ref-type="fig"}). In the Igκ locus, 111 potentially functional Vκ and 3 Jκ genes were determined ([Figure 2A](#F2){ref-type="fig"}). For Igλ, 58 Vλ, and 11 Jλ genes were categorized as potentially functional ([Figure 2A](#F2){ref-type="fig"}). By analyzing the functional gene segment sequences, we designed 5′ forward primers spanning the first 21--25 nt of the framework 1 (FR1) regions in V-gene segments. In total, based on sequence homology, 52, 71, and 36 5′ primers were synthesized for heavy, kappa, and lambda chain amplification, respectively ([Figure 2B](#F2){ref-type="fig"} and [Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}). Two sets of 3′ reverse primers were sequentially used to anneal to the Ig constant regions during PCR reactions ([Figure 2C](#F2){ref-type="fig"} and [Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}). After two rounds of PCR, products were checked on 96-well E Gels. 45/88 (51%) positive wells were observed for the heavy chain amplification, while 36/88 (41%) and 16/88 (18%) positive wells for the lambda and kappa chain amplifications, respectively. From the 88 cells sorted, we successfully recovered 24 paired heavy- and light-chain variable domain genes ([Table 1](#T1){ref-type="table"}).

All of the amplicons from the second PCR reactions with the expected sizes ([Figure 2D](#F2){ref-type="fig"}) were sequenced and annotated initially by V-Quest through IMGT with human Ig germline database as reference to delineate CDR boundary. Subsequently, we used IgBLAST to determine the closest functional V, D, and J segments using in-house guinea pig germline database derived from the work of [@B7].

Guinea Pig mAb Cloning and Expression
-------------------------------------

Based on the V and J segments assigned with IgBLAST, the corresponding cloning PCR primers for each mAb were chosen from the seamless cloning primer sets shown in [Tables 5](#T5){ref-type="table"}--[7](#T7){ref-type="table"}. Cloning PCR products were further inserted into expression vectors by GeneArt seamless cloning and assembly kit, followed by sequencing verification. By co-transfection of heavy- and light-chain expression vectors into 293F cells, 20 out of 24 (83%) chimeric mAbs were efficiently expressed and purified from cell culture supernatants. Genetic analysis grouped them into nine clonal lineages, with most lineages consisting single member while three lineages (\#1, \#5, and \#7) containing multiple clonal members ([Figure 2E](#F2){ref-type="fig"} and [Table 8](#T8){ref-type="table"}). Clonal dominance is notable: one clonal lineage \#5 ([Figure 2E](#F2){ref-type="fig"} and [Table 8](#T8){ref-type="table"}) consisting of 10 clonal members predominantly accounts for 50% of the total sorted B cells. Somatic hypermutation (SHM) levels (Mut %) of the sorted B cells were calculated as percentage of nucleotide sequence divergence from the germline V gene sequences ([Table 8](#T8){ref-type="table"}). We found moderate level of SHM for the VH and VK/VL of the sorted B cells, ranging from 2.9 to 11.5%, and 0.7 to 12%, respectively ([Figure 2E](#F2){ref-type="fig"} and [Table 8](#T8){ref-type="table"}), consistent with the SHM level of Env-specific mAbs elicited by immunization in rhesus monkeys reported previously ([@B32]).

###### 

Genetic and binding specificity analysis of guinea pig mAb variable region sequences^‡^.

                         VDJ segments_CDRH3                                    VJ segments_CDRL3                             Binding specificity
  ----------- ------ --- ------------------------- ------ -------------------- ---------------------- ------ --------------- ---------------------
  nAbs        CP2    1   VH3-197_D6_JH4_CDR3_17    7.5    TRNLLLSGVESTGAFDV    VL3-41_JL_3\_CDR3_13   2.0    AITLGSGSIFQSV   Env (V3)
              CP94   1   VH3-197_D6_JH4_CDR3_17    8.4    TRNLLLSGVESTGAFDV    VL3-41_JL_3\_CDR3_13   2.0    AITLGSGSIFQSV   Env (V3)
              CP6    2   VH3-197_D18_JH4_CDR3_12   11.0   AKNKGETASFDV         VL3-41_JL_1\_CDR3_13   6.0    SIARVSGNNIQWV   Env (V3)
              CP10   3   VH3-197_D3_JH4_CDR3_15    9.1    AKNGDTSNGETTPDV      VL3-41_JL_1\_CDR3_13   6.0    TVAHVSGNAFQWV   Env (V3)
              CP67   4   VH3-197_D17_JH4_CDR3_17   7.3    AKNLLLSEATSTGAFDV    VL4-82_JL_1\_CDR3_9    12.0   AVGHSAGWV       Env (V3)
  Non- nAbs   CP3    5   VH3-183_D15_JH4_CDR3_18   8.0    TRGPYYRWGTWSLYYFDI   VL4-82_JL_1\_CDR3_9    6.6    AVGYNTGWV       Env, unknown
              CP7    5   VH3-183_D15_JH4_CDR3_18   11.2   ARAPYYKWGTWSLYYFDI   VL4-82_JL_1\_CDR3_9    8.4    AVGHSAGWV       Env, unknown
              CP13   5   VH3-183_D15_JH4_CDR3_18   6.9    ARGAYYRWGTWSLYYFDV   VL4-82_JL_1\_CDR3_9    5.1    AVGYSAGWV       Env, unknown
              CP37   5   VH3-183_D15_JH4_CDR3_18   7.7    ARGAYYKWGTWTLYYFDL   VL4-82_JL_1\_CDR3_9    7.6    AVGHSAGWV       Env (unknown)
              CP53   5   VH3-183_D15_JH4_CDR3_18   11.4   ARAPYYKWGTWSLYYFDI   VL4-82_JL_1\_CDR3_9    7.6    AVGHSAGWV       Env (unknown)
              CP61   5   VH3-183_D15_JH4_CDR3_18   7.7    ARGPYYRWGTWSLYYFDI   VL4-82_JL_1\_CDR3_9    5.8    AVGYSAGWV       ^∗^Env (unknown)
              CP62   5   VH3-183_D15_JH4_CDR3_18   11.5   ARAPYYKWGTWSLYYFDI   VL4-82_JL_1\_CDR3_9    9.8    AVGHSAGWV       ^∗^Env (unknown)
              CP73   5   VH3-183_D15_JH4_CDR3_18   11.1   ARGPYYRWGTWSLYYFDI   VL4-82_JL_1\_CDR3_9    7.6    AVGYSAGWV       Env (unknown)
              CP91   5   VH3-183_D15_JH4_CDR3_18   7.6    ARGPYYKWGTWSLYYFDI   VL4-82_JL_1\_CDR3_9    7.3    AVGYSAGWV       ^∗^Env (unknown)
              CP92   5   VH3-183_D15_JH4_CDR3_18   7.0    ARGAYYKWGTWTLYYFDL   VL4-82_JL_1\_CDR3_9    8.0    AVGYSAGWI       Env (unknown)
              CP68   6   VH3-183_D15_JH2_CDR3_18   8.3    QEGSYYKWGMGMTSNHHA   VL4-82_JL_1\_CDR3_9    6.6    AVGYSAGWV       Env (unknown)
              CP58   7   VH3-230_D31_JH2_CDR3_7    5.1    TTTGLTY              Vk1-201_Jk2_CDR3_9     3.6    WQYDKLPLT       Env (unknown)
              CP63   7   VH3-230_D17_JH2_CDR3_7    2.9    TTTGLGY              Vk1-201_Jk2_CDR3_9     3.5    WQYDKLPLT       Env (unknown)
              CP66   8   VH3-139_D27_JH4_CDR3_7    2.9    ARMVVDV              Vk4-83_Jk2_CDR3_9      0.7    MQDYNPPYT       Env (unknown)
              CP82   9   VH3-80_D31_JH4_CDR3_17    3.7    ARDGWEEYMWGGSFLDL    Vk4-28_Jk3_CDR3_11     1.9    LQYYDFPNT       Env (unknown)
                                                                                                                             

‡

Heavy- and light-chain sequences of mAbs cloned were analyzed by IgBLAST and assigned to the closest V, D, and J germline genes. Clonal lineage criteria are shown in

Figure 2

. Somatic hypermutation level (Mut %) were calculated as percentage of nucleotide sequence divergence from germline V gene sequences.

∗

ELISA/BLI negative. Specificity inferred by clonal lineage analysis, e.g., belonging to the same lineage with BG505 SOSIP binding clones.

Guinea Pig mAb Characterization
-------------------------------

Since we sorted HIV-1 Env-specific B cells for Ig encoding gene analysis and mAb cloning, we further verified the mAb binding specificity by ELISA binding assays, with BG505 SOSIP pre-coated on ELISA plates and mAbs serving as analytes. We found that 16/20 (80%) of the guinea pig mAbs recognized the antigen probe, BG505 SOSIP trimer by ELISA assay ([Figure 3A](#F3){ref-type="fig"} and [Tables 1](#T1){ref-type="table"}, [8](#T8){ref-type="table"}). The predominant clonal lineage \#5, consists seven members that bind BG505 SOSIP well ([Figure 3A](#F3){ref-type="fig"} and [Table 8](#T8){ref-type="table"}) and three members (CP61, 62, and 91) showing negligible BG505 SOSIP binding assayed by ELISA ([Figure 3A](#F3){ref-type="fig"} and [Table 8](#T8){ref-type="table"}). This observation demonstrates the heterogeneity of affinity for antigen between clonal members within the same clonal lineage.

![Binding specificity and neutralization profile of guinea pig mAbs isolated from PBMCs. **(A)** Reactivity of guinea pig mAbs to BG505 SOSIP trimer by ELISA assay. Strong binding (OD450 \>0.5); weak/no binding (weak-binding, 0.2\<OD450 \<0.5; no binding, OD450 \<0.2). Data were duplicated, with the mean of OD450 shown. **(B)** Reactivity of selected guinea pig mAbs to BG505 SOSIP trimer by BLI assay. (Upper) BLI binding curves of mAbs from clonal lineages \#5 and \#7. mAbs were captured by anti-human IgG Fc biosensors, followed by interaction with BG505 SOSIP trimer in twofold dilution series starting from 1000 to 250 nM, with the curves of 1000 nM shown. (Lower) mAb-BG505 SOSIP trimer binding kinetic parameters, shown as measured value ± standard error. *k*~on~, on-rate or association rate; *k*~off~, off-rate or dissociation rate; *K*~D~, binding affinity constants (dissociation constant), determined as *k*~off~/*k*~on~. **(C)** Summary of BG505 SOSIP trimer reactivity by ELISA and BLI. Of 20 mAbs expressed (left) 16 (80%) and (right) 17 (85%) show detectable binding activity to BG505 SOSIP trimers by ELISA and BLI assay, respectively. **(D)** Pie chart showing the binding specificity of the 16 BG505 SOSIP-reactive mAbs isolated from guinea pig 1567 by ELISA assay. V3-reactivity was assessed by positive reactivity (OD450 \>0.2) with peptides derived from V3 regions of HIV isolates BG505 or JR-FL. **(E)** Neutralization potency (IC~50~, μg/mL) of isolated mAbs against Env-pseudotyped viruses. mAbs are color-coded to differentiate corresponding clonal lineage. Animal 1567 plasma neutralization titers (ID~50~) against HXBc2, ZM109, BG505 N332 (autologous virus corresponding to the immunogen, BG505 SOSIP, which contains N332 glycan), and JR-FL pseudoviruses were shown for comparison. ID~50~ are values of the plasma reciprocal dilution factors at which 50% inhibition of infection are achieved in the assay. The background neutralization ID~50~ titer threshold is set as \<10. ND, not determined. ELISA binding to BG505 SOSIP trimer, BG505 gp120 monomer, BG505 V3 and JR-FL V3 peptide are also shown. Broadly neutralizing mAb, VRC01 (CD4bs epitope specific) is shown as control. Data are duplicated with the mean of IC~50~/ID~50~ shown.](fmicb-10-00672-g003){#F3}

We subsequently used BLI assay to characterize the antigen binding affinity of selected guinea pig mAbs from lineages \#5 and \#7, which consist mAb members with negative antigen binding activity assessed by ELISA ([Figure 3B](#F3){ref-type="fig"} and [Table 8](#T8){ref-type="table"}). In this BLI assay, the mAbs bearing the human Fc portion were initially captured to the anti-human IgG Fc biosensors followed by the association reaction with BG505 SOSIP analytes, which assesses the binding reaction in an orientation different from that in the ELISA assay. Thus, the BLI assay result would complement the ELISA measurement, especially for epitopes sensitive to antigen pre-coating. We selected a few members ([Table 8](#T8){ref-type="table"}) from the clonal lineage \#5 with different ELISA binding profiles, including CP3 (high binding), CP53 (weak binding), and CP61, 62, and 91 (no binding), as well as CP58 (no ELISA binding) in clonal lineage \#7 for BLI assay. We found that consistent with the ELISA assay, CP3 and CP53 showed decent binding signal for BG505 SOSIP ([Figure 3B](#F3){ref-type="fig"}), while no binding signal was observed for CP61, 62, and 91. Interestingly, CP53 showed affinity (dissociation constant *K*~D~ approximately 2 nM) for BG505 SOIP equivalent to CP3 in this BLI assay, while its binding to BG505 SOSIP was weaker than CP3 in ELISA assay ([Figure 3A](#F3){ref-type="fig"}). For mAbs from lineage \#7, CP58 and CP63 displayed moderate (*K*~D~ = 26 nM) and strong (*K*~D~ = 2.5 nM) binding affinity for BG505 SOSIP ([Figure 3B](#F3){ref-type="fig"}), respectively, while they showed no and weak ELISA binding to BG505 SOSIP, separately. The overall improved antigen binding profiles of CP58 and CP63 from lineage \#7 by BLI assay indicate that their cognate epitope on the BG505 SOSIP trimer is sensitive to the antigen pre-coating in the ELISA assay. Our results suggests that the results of ELISA and BLI binding assays corroborate with each other, while the sensitivity of BLI assay is often higher than ELISA. Based on BLI assay, 85% (17/20) of the guinea pig mAbs recognized the antigen probe, BG505 SOSIP trimer ([Figure 3C](#F3){ref-type="fig"} and [Tables 1](#T1){ref-type="table"}, [8](#T8){ref-type="table"}). Therefore, BLI assay could be used to complement ELISA for assessing Ab-Antigen binding ([Figure 3C](#F3){ref-type="fig"}).

We then estimated the precision of our Ag-specific class-switched B cell sorting and Ig cloning method by consolidating the results of Ag-binding assays (ELISA and BLI) and genetic analysis. Since B cells derived from the same clonal lineage share similar Ag recognition determinants, we used clonal lineage information of the sorted mAbs to infer the Ag-binding specificity of mAbs with inappreciable Ag ELISA/BLI binding phenotypes. For example, CP61, 62, and 91 from clonal lineage \#5 barely bound BG505 SOSIP ([Figure 3A,B](#F3){ref-type="fig"}). However, their related mAb clones such as CP3 and CP92 from lineage \#5 showed strong binding with BG505 SOSIP trimer by ELISA and/or BLI ([Figure 3A,B](#F3){ref-type="fig"}). Thus, we inferred the Ag specificity of CP61, 62, and 91 to be the same with CP3 and CP92 ([Table 8](#T8){ref-type="table"}). Such mAbs showing negative antigen binding phenotypes in ELISA/BLI assays possess low affinity for BG505 SOSIP ([Figure 3B](#F3){ref-type="fig"}). However, in the FACS sorting procedure, streptavidin-PE or -APC conjugates were premixed with the biotin-labeled BG505 SOSIP trimers to form high-order sorting probe complex with elevated binding valence, which could presumably facilitate the binding and isolation of B cells with low affinity B cell receptors encoding the above stated mAbs. Thus, in addition to functional antigen-binding assays, clonal lineage analysis is informative for determining the antigen-binding specificity of low affinity mAbs. To the end, we concluded that all the 20 mAbs derived from the Ag-selection based sorting/cloning study were Ag-specific ([Tables 1](#T1){ref-type="table"}, [8](#T8){ref-type="table"}), with various affinities for the cognate Ag ([Figure 3B](#F3){ref-type="fig"}), belonging to nine clonal lineages ([Figure 2E](#F2){ref-type="fig"} and [Table 8](#T8){ref-type="table"}). Thus, the sorting and cloning method is feasible for guinea pig Ag-specific B cell analysis, with virtually 100% precision ([Table 1](#T1){ref-type="table"}).

To map the binding epitopes of the mAbs, we tested their reactivity against V3 peptides derived from the Envs of BG505 and JR-FL, since the V3 region is one of the immunodominant epitopes of HIV Env shown by previous studies ([@B21]; [@B31]). We found that five mAbs including CP2, CP6, CP10, CP67, and CP94 bound the autologous BG505 V3 peptide well ([Figure 3D,E](#F3){ref-type="fig"}), while three of them (CP2 and CP94 from clonal lineage \#1, and CP10 from clonal lineage \#3) bound V3 peptide derived from isolate JR-FL with high binding activity ([Figure 3E](#F3){ref-type="fig"}), suggesting the prominent immunogenicity of the BG505 SOSIP V3 region in this study. The substantial frequency of V3-reactive mAbs resulted from this immunization is consistent with the notion that V3 region is still a prominent immunogenic element of the current generation of HIV-1 Env trimer immunogen such as BG505 SOSIP.

To characterize the function of the isolated mAbs further, we analyzed their neutralization capacity via the TZM-bl assay utilizing a panel of pseudotyped HIV-1 viruses. Five mAbs from four clonal lineages neutralized the tier 1 virus ZM109, which is consistent with the polyclonal plasma neutralization capacity against the same virus ([Figure 3E](#F3){ref-type="fig"}). All the tier 1 virus neutralizing antibodies recognize V3 region ([Figure 3E](#F3){ref-type="fig"}). It is notable that none of the cloned mAbs from this study neutralizes the autologous virus BG505 N332 as the plasma does ([Figure 3E](#F3){ref-type="fig"}). BG505 SOSIP trimer contains the conserved V3 glycan N332 ([@B23]). Therefore, virus BG505 N332 is used as the virus for assessing mAb and plasma autologous neutralization activities.

Discussion
==========

Small animal models are typically utilized for initial preclinical evaluation of vaccine candidates *in vivo*. The guinea pig model, compared to mouse, is more immunologically similar to human and has an adequate amount of blood volume for initial immunological analysis ([@B19]). Some recent studies have used guinea pig model to evaluate the immunogenicity of HIV Env-based immunogen candidates and immunization strategies ([@B18]; [@B5]; [@B38]). However, characterization of B cell response in these studies is still limited to the polyclonal level. Besides serum neutralization assay and epitope mapping, a high-resolution strategy to delineate B cell response is desirable, as it will substantially aid vaccine evaluation and vaccine design.

There are two major technique hurdles obstructing single B cell analysis in guinea pigs: (i) the lack of sophisticated B cell surface marker antibody panels for identifying guinea pig memory B cells, in contrast to mouse, macaque, and human ([@B28], [@B27]; [@B26]), and (ii) the unavailability of primer sets for amplifying guinea pig IGH- and light-chain encoding genes. In this study, we took advantage of the expression of B cell receptors (BCR) on the surface of IgG^hi^ IgM^lo^ B cells, which renders the corresponding B cells recognizable by antigens and anti-IgG secondary antibodies. Using FACS sorting technique with fluorochrome-conjugated antigen and anti-guinea pig IgG secondary antibody cocktails, we successfully isolated antigen-specific guinea pig class-switched IgG^hi^ B cells for further analysis. The combination of antigen and anti-guinea pig IgG secondary antibody is sufficient to capture antigen-specific B cells, as demonstrated that \>85% mAbs cloned from the sorted B cells are specifically reactive to the sorting antigen probe. In addition, we designed a set of guinea pig Ig gene-specific primers based on recently annotated guinea pig Ig gene cluster mapping ([@B7]), by using a pool of 5′ forward primers derived from the framework 1 of guinea pig heavy- and light-chain variable domains, and 3′ reverse primers annealing to the constant regions of guinea pig heavy/light chains. We recovered guinea pig Ig sequences by a semi-nested PCR strategy similar to the strategies proposed for mouse ([@B27]), rabbit ([@B25]), macaque ([@B26]), and human ([@B28]). Approximately 50--60% heavy and light chain recovery efficiency was observed, while 27% of sorted cells have paired heavy and light chain amplicons for further functional analysis. In complement to a previous elegant study focused on enriching plasmablast cells (PCs), which contain abundant endoplasmic reticulum (ER) with ER-specific fluorescent dye to recover Ig encoding genes ([@B9]), our platform is applicable to analyze various class-switched B cell populations including memory B cells and a subset of PCs, which remain expression of cell surface-bound IgGs.

We isolated five mAbs from four clonal lineages encoding tier 1 virus neutralizing antibodies targeting the V3 crown of the HIV-1 Env ([Figure 3E](#F3){ref-type="fig"} and [Table 8](#T8){ref-type="table"}). The failure of these V3-specific mAbs to neutralize tier 2 viruses ([Figure 3E](#F3){ref-type="fig"}) is consistent with the notion that the V3 crown is mostly occluded by other structural elements such as the V1V2 loops and glycans on the static (closed) HIV Env trimers of primary isolates (e.g., tier 2 viruses such as BG505) ([@B8]; [@B14]; [@B11]). However, these V3-specific mAbs are able to access the V3 crown on the tier 1 virus Env spikes, which sample more opened configurations than tier 2 viruses ([@B39]; [@B31]), to mediate tier 1 virus neutralization. In addition, we found that these V3-specific mAbs all use VH3-197/JH4 and mostly VL3-41 segments ([Table 8](#T8){ref-type="table"}). Moreover, we identified a predominant clonal lineage consisting of 10 clonal members (Lineage \#5, [Table 8](#T8){ref-type="table"}) with the usage of VH3-183_D15_JH4 and VL4-82_JL1 gene segments ([Table 8](#T8){ref-type="table"}), which accounts for 50% of the well-expressed mAbs derived from the Ag-specific IgG^hi^ IgM^lo^ B cells with paired heavy/light chains. The observed skewed Ig gene segment usage highlights the immunodominance of certain B cell lineages in the Env-specific B cell repertoire following BG505 SOSIP trimer immunization.

Of note, none of the mAbs isolated from the PBMCs (∼10 million) of animal 1567 in this study displayed neutralization against the autologous tier 2 virus, BG505, which is consistent with the observed relatively low frequency of Env-specific B cells (0.11% in class-switched B cells) in the PBMC compartment of this animal ([Figure 1C](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Sampling lymphoid tissues including spleen and lymph nodes where B cell germinal center activation primarily occurs ([@B30]) may lead to capturing the antigen-specific IgG^hi^ B cells at higher frequency. In a related study ([@B12]) using similar BG505 SOSIP sorting probes, we found that about 3% of class-switched IgG^hi^ B cells are antigen-specific in splenocytes, which is 30-fold higher than that in PBMCs ([Figure 1C](#F1){ref-type="fig"}). Subsequently, using splenic B cells and a more selective sorting strategy, we were able to capture the BG505 Env-specific B cells, which encode the antibodies recapitulating the autologous serum neutralization capacity against the BG505 virus with this cloning platform ([@B12]). Therefore, this method could be further applied to examine Ag-specific B cell repertoire from different tissue compartments in future studies.

This method enables us sampling 27% Ag-specific B cells with paired heavy- and light-chain from 88 Ag-reactive single IgG^hi^ IgM^lo^ B cells (out of 10 million PBMCs) for functionality analysis, defining clonal lineage relationship between sorted B cells, and delineating epitope binding specificity of selected mAb clones ([Figure 3](#F3){ref-type="fig"} and [Table 8](#T8){ref-type="table"}). Our result demonstrates the essential efficiency and feasibility of this platform for guinea pig single B cell analysis. The relatively low frequency of sorted cells with paired heavy and light chain amplicons may be caused by Ig gene polymorphisms ([@B4]). We anticipate that with the improvement in guinea pig Ig primer set design in the future, by primer optimization informed by individualized V gene sequencing ([@B4]), this platform can be more efficient and comparable to previous methods developed for mouse, macaque, and human ([@B27]; [@B34]; [@B37]).

With the method developed herein, specific antibody lineages responsible for neutralization activity can be identified and characterized from vaccinated animals. In addition, the primers designed for guinea pig single cell RT-PCR can be applied for next-generation Ig sequencing library preparation to interrogate B cell clonal lineage evolution during immunization. All the information gleaned from these analyses will contribute to a better understanding of immune response quality and detailed specificities to inform future vaccine design. Furthermore, this method enables the isolation of Ag-specific mAbs for developing therapeutic reagents in guinea pig model. Thus, the platform described here will clearly benefit future B cell response analyses at both the clonal and repertoire levels, which helps to facilitate future efforts in immune response characterization as well as genetic and functional interpretation of the guinea pig model for applicable infectious diseases, including but not limited to HIV-1.
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